Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.06)
# 3,872
Out of 5,242 analysts
318
Total ratings
25.87%
Success rate
-14.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $11.06 | +216.60% | 16 | May 18, 2026 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $9 → $10 | $1.73 | +479.71% | 2 | May 14, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $7 → $10 | $3.92 | +155.10% | 4 | May 12, 2026 | |
| ARTV Artiva Biotherapeutics | Maintains: Buy | $15 → $35 | $7.95 | +340.25% | 3 | May 8, 2026 | |
| TGTX TG Therapeutics | Maintains: Buy | $60 → $70 | $38.91 | +79.93% | 2 | May 6, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $30 | $17.20 | +74.42% | 1 | Apr 28, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $65 → $50 | $28.52 | +75.32% | 6 | Apr 20, 2026 | |
| ANAB AnaptysBio | Reiterates: Buy | $66 | $59.43 | +11.06% | 15 | Mar 30, 2026 | |
| ATOS Atossa Therapeutics | Maintains: Buy | $7 → $25 | $4.88 | +412.30% | 15 | Mar 26, 2026 | |
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $2.85 | +953.44% | 15 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $38 | $13.50 | +181.48% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $3.16 | +121.87% | 13 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $23.69 | +35.11% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $49 | $17.89 | +173.90% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $34.85 | +34.86% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.79 | +964.43% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.59 | +93.05% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.00 | +1,100.00% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.20 | +618.75% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $3.43 | +1,066.18% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.40 | +1,900.00% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $0.9683 | +1,965.48% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.02 | +299.33% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $6.14 | +4,460.26% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.34 | +241.88% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.92 | +927.40% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.07 | +487.28% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.20 | +8,189.90% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.26 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.53 | - | 1 | Apr 25, 2024 |
MiNK Therapeutics
May 18, 2026
Reiterates: Buy
Price Target: $35
Current: $11.06
Upside: +216.60%
Autolus Therapeutics
May 14, 2026
Maintains: Buy
Price Target: $9 → $10
Current: $1.73
Upside: +479.71%
SAB Biotherapeutics
May 12, 2026
Maintains: Buy
Price Target: $7 → $10
Current: $3.92
Upside: +155.10%
Artiva Biotherapeutics
May 8, 2026
Maintains: Buy
Price Target: $15 → $35
Current: $7.95
Upside: +340.25%
TG Therapeutics
May 6, 2026
Maintains: Buy
Price Target: $60 → $70
Current: $38.91
Upside: +79.93%
First Tracks Biotherapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $30
Current: $17.20
Upside: +74.42%
Agios Pharmaceuticals
Apr 20, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $28.52
Upside: +75.32%
AnaptysBio
Mar 30, 2026
Reiterates: Buy
Price Target: $66
Current: $59.43
Upside: +11.06%
Atossa Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $7 → $25
Current: $4.88
Upside: +412.30%
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $2.85
Upside: +953.44%
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $13.50
Upside: +181.48%
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.16
Upside: +121.87%
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $23.69
Upside: +35.11%
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $17.89
Upside: +173.90%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $34.85
Upside: +34.86%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.79
Upside: +964.43%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.59
Upside: +93.05%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $1.00
Upside: +1,100.00%
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.20
Upside: +618.75%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $3.43
Upside: +1,066.18%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.40
Upside: +1,900.00%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $0.9683
Upside: +1,965.48%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $9.02
Upside: +299.33%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $6.14
Upside: +4,460.26%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.34
Upside: +241.88%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.92
Upside: +927.40%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $3.07
Upside: +487.28%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.20
Upside: +8,189.90%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.53
Upside: -